Fasting Insulin: Which Tests to Order Alongside for a Complete Metabolic Picture

What Fasting Insulin Actually Measures

Fasting insulin quantifies the concentration of insulin circulating after an 8-to-12-hour fast, reflecting basal pancreatic beta-cell output. A result tells your clinician how hard the pancreas is working to maintain normal blood sugar at rest. High values signal that tissues are resisting insulin's signal, forcing greater secretion to compensate.

The American Association of Clinical Endocrinology (AACE) identifies insulin resistance as the core driver of metabolic syndrome, a cluster of conditions including abdominal obesity, dyslipidemia, hypertension, and dysglycemia that raises cardiovascular risk [1]. Fasting glucose may remain within reference range for a decade while insulin levels climb. That delay is the diagnostic gap this test fills.

Most commercial assays report a reference interval of roughly 2.6 to 24.9 µIU/mL, although lab-specific ranges differ because insulin immunoassays lack universal standardization [2]. A value of 10 µIU/mL or below is often cited as optimal in metabolic health literature, while values above 15 µIU/mL in the presence of normal glucose strongly suggest compensatory hyperinsulinemia.

Ordering fasting insulin without companion labs, however, leaves the clinical picture incomplete. Below is the rationale for each test that should accompany it.

Fasting Glucose and HOMA-IR: The First Pairing

Fasting glucose is the single most important companion to fasting insulin. Together they produce the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated as (fasting insulin in µIU/mL × fasting glucose in mg/dL) ÷ 405.

HOMA-IR was validated against the hyperinsulinemic-euglycemic clamp (the gold standard for measuring insulin sensitivity) in the original 1985 study by Matthews et al. and has been used in large-scale epidemiologic research ever since [3]. A HOMA-IR score of 1.0 is considered ideal. Scores above 2.5 are widely used as the threshold for insulin resistance, and scores above 5.0 indicate severe resistance [4].

Why not just order fasting glucose alone? Because glucose is the last domino to fall. The Whitehall II prospective cohort study (N=6,538) showed that insulin sensitivity declined for 13 years before fasting glucose finally crossed the diabetic threshold of 126 mg/dL [5]. A patient with a fasting glucose of 92 mg/dL and a fasting insulin of 22 µIU/mL has a HOMA-IR of 5.0. Their glucose looks normal. Their metabolic trajectory does not.

One practical note: both draws must come from the same fasting blood sample. Insulin's half-life in plasma is roughly 4 to 6 minutes, so even a short delay between collections can introduce error.

HbA1c: The 90-Day Rearview Mirror

HbA1c provides a 90-day weighted average of blood glucose and should be ordered alongside every fasting insulin panel. The American Diabetes Association (ADA) recognizes HbA1c of 5.7% to 6.4% as the prediabetes range and 6.5% or higher as diabetes [6].

While fasting insulin and HOMA-IR capture what is happening right now, HbA1c reveals what has been happening over the prior two to three months. The combination matters clinically. A patient with a HOMA-IR of 3.2 and an HbA1c of 5.4% is still compensating effectively. The same HOMA-IR with an HbA1c of 6.1% signals that compensation is failing.

There are known limitations. HbA1c may underestimate glycemia in patients with hemolytic anemias, iron deficiency, or hemoglobin variants such as HbS or HbC [7]. In those populations, fructosamine or glycated albumin may serve as alternatives, though neither is included in standard metabolic panels.

Lipid Panel: Triglyceride-to-HDL Ratio as an Insulin Resistance Proxy

Order a standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) at the same draw. The triglyceride-to-HDL-C ratio is a well-studied surrogate marker for insulin resistance, especially in non-Hispanic white and Mexican American populations [8].

A triglyceride-to-HDL ratio above 3.0 (using mg/dL) correlates with increased small dense LDL particles and higher HOMA-IR scores. In the Strong Heart Study (N=2,962 American Indian participants), this ratio predicted incident diabetes independently of BMI [9]. The 2023 AACE Consensus Statement on insulin resistance recommends including triglycerides and HDL-C in any metabolic workup [1].

Atherogenic dyslipidemia (high triglycerides, low HDL-C, high small dense LDL) is a direct metabolic consequence of hepatic insulin resistance. Seeing it on the same panel as an elevated fasting insulin confirms a consistent pathophysiologic pattern rather than an isolated lab abnormality.

C-Peptide: Separating Secretion from Exogenous Insulin

C-peptide is co-secreted with insulin in equimolar amounts but has a longer half-life (roughly 30 minutes versus 4 to 6 minutes for insulin) and is not cleared by the liver on first pass [10]. It answers a different question than fasting insulin: how much insulin is the pancreas actually making?

Order C-peptide when:

• A patient is already on exogenous insulin and you need to assess residual beta-cell function.
• Fasting insulin is unexpectedly low and you suspect insulinoma or factitious insulin use.
• You are differentiating type 1 from type 2 diabetes in an adult with ambiguous presentation.

The Endocrine Society's Clinical Practice Guideline on hypoglycemia in adults recommends measuring C-peptide, proinsulin, and insulin simultaneously during a supervised fast when insulinoma is suspected [11]. For routine metabolic screening in a patient not on insulin, C-peptide adds confirmation but is not strictly required at every draw.

A fasting C-peptide above 1.1 ng/mL paired with a fasting insulin above 15 µIU/mL and a HOMA-IR above 2.5 forms a consistent triad of endogenous hyperinsulinemia driven by tissue resistance.

Liver Enzymes and Uric Acid: The Hepatic Connection

Insulin resistance and non-alcoholic (now termed metabolic dysfunction-associated) steatotic liver disease (MASLD) are bidirectional. Hepatic fat accumulation worsens insulin resistance, and hyperinsulinemia drives hepatic de novo lipogenesis, depositing more fat in the liver [12].

Order ALT and AST at baseline. An ALT above 19 U/L in women or above 30 U/L in men has been proposed by some hepatologists as the upper threshold warranting further evaluation, even though many labs set the reference ceiling higher [13]. Elevated ALT in the context of high fasting insulin and elevated triglycerides should prompt consideration of abdominal ultrasound or FibroScan.

Uric acid is another underappreciated companion marker. Hyperuricemia (above 7.0 mg/dL in men, above 6.0 mg/dL in women) frequently clusters with insulin resistance because insulin reduces renal uric acid clearance [14]. The combination of elevated fasting insulin, raised triglycerides, and high uric acid points strongly toward metabolic syndrome even if glucose remains normal.

SHBG and Sex Hormones: When PCOS or Hypogonadism Is on the Table

Sex hormone-binding globulin (SHBG) is inversely correlated with insulin levels. Hyperinsulinemia suppresses hepatic SHBG production, which increases free testosterone in women (driving PCOS features) and may paradoxically contribute to lower total testosterone in men with obesity [15].

The Endocrine Society's 2023 PCOS guideline recommends assessing insulin resistance in all women with polycystic ovary syndrome, noting that up to 70% of women with PCOS exhibit insulin resistance independent of BMI [16]. For these patients, pairing fasting insulin with total testosterone, free testosterone, DHEA-S, and SHBG is standard.

In men, the AUA/Endocrine Society guidelines on testosterone deficiency recommend checking fasting glucose or HbA1c alongside total testosterone [17]. Adding fasting insulin to that workup can identify the metabolic driver behind low SHBG and borderline-low total testosterone, an increasingly common presentation in men with visceral adiposity.

High-Sensitivity CRP: Inflammatory Context

Chronic low-grade inflammation accompanies insulin resistance. High-sensitivity C-reactive protein (hs-CRP) adds prognostic information.

The Jupiter trial (N=17,802) demonstrated that rosuvastatin reduced cardiovascular events in patients with elevated hs-CRP (above 2.0 mg/L) even when LDL-C was below 130 mg/dL [18]. While hs-CRP is not specific to insulin resistance, an elevated hs-CRP alongside hyperinsulinemia and atherogenic dyslipidemia strengthens the case for aggressive metabolic intervention.

The AHA/CDC joint statement classifies hs-CRP below 1.0 mg/L as low cardiovascular risk, 1.0 to 3.0 mg/L as moderate, and above 3.0 mg/L as high [19]. A single measurement can be confounded by acute infection or injury, so repeat testing at least two weeks after any acute illness is advised.

How to Lower Fasting Insulin

Reducing fasting insulin centers on improving tissue insulin sensitivity. Four evidence-based strategies have the strongest support.

Caloric restriction and weight loss. A 5% to 7% reduction in body weight improves insulin sensitivity measurably. The Diabetes Prevention Program (DPP, N=3,234) showed that lifestyle intervention producing modest weight loss reduced diabetes incidence by 58% over 2.9 years compared with placebo [20]. Fasting insulin levels declined in the intervention group in parallel with weight loss.

Exercise. Both aerobic and resistance training improve insulin-mediated glucose uptake. A 2016 meta-analysis of 11 RCTs (N=846) found that combined aerobic and resistance exercise reduced HOMA-IR by 22% in adults with type 2 diabetes [21].

Metformin. In the DPP, metformin 850 mg twice daily reduced diabetes incidence by 31% [20]. Metformin lowers fasting insulin primarily by suppressing hepatic glucose output and modestly improving peripheral insulin sensitivity.

GLP-1 receptor agonists. Semaglutide 2.4 mg weekly produced 14.9% mean body weight loss versus 2.4% with placebo at 68 weeks in STEP-1 (N=1,961), with corresponding reductions in fasting insulin and HOMA-IR [22]. Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrated even greater weight loss (up to 22.5% at 72 weeks in SURMOUNT-1, N=2,539), with proportional improvements in insulin sensitivity markers [23].

Dr. Ania Jastreboff, principal investigator of the SURMOUNT-1 trial, stated: "The magnitude of weight reduction and the improvements in cardiometabolic risk factors are beyond what we have previously seen with anti-obesity medications" [23].

How to Raise Fasting Insulin (and When It Matters)

Low fasting insulin is less commonly discussed but clinically relevant in specific scenarios. A fasting insulin below 2 µIU/mL with a fasting glucose above 126 mg/dL points toward insulin-deficient diabetes (type 1 or latent autoimmune diabetes of adults, LADA). In that context, add glutamic acid decarboxylase (GAD-65) antibodies, islet cell antibodies (ICA), and IA-2 antibodies to distinguish autoimmune beta-cell destruction from type 2 diabetes [24].

Raising endogenous insulin production pharmacologically is possible with sulfonylureas and meglitinides, both of which stimulate beta-cell secretion. These drugs are appropriate only when beta-cell reserve remains. They carry hypoglycemia risk and are not first-line for most patients.

In patients with type 1 diabetes or advanced type 2 diabetes with beta-cell exhaustion, exogenous insulin therapy replaces what the pancreas can no longer produce. The goal is not to raise endogenous fasting insulin but to provide physiologic basal coverage.

Putting the Panel Together: A Practical Ordering Guide

The table below organizes companion tests by clinical scenario.

Routine metabolic screening (all patients): Fasting insulin, fasting glucose (calculate HOMA-IR), HbA1c, lipid panel (with triglyceride-to-HDL ratio), ALT.

Suspected PCOS: Add total testosterone, free testosterone, DHEA-S, SHBG.

Suspected MASLD: Add AST, GGT, uric acid, comprehensive metabolic panel. Consider FibroScan referral.

Suspected autoimmune diabetes or unusually low insulin: Add C-peptide, GAD-65 antibodies, IA-2 antibodies.

Cardiovascular risk stratification: Add hs-CRP, lipoprotein(a), apolipoprotein B.

The AACE 2023 Consensus Statement recommends that clinicians "consider measuring fasting insulin and using HOMA-IR as a practical tool to identify insulin resistance in at-risk patients, particularly those with metabolic syndrome, PCOS, or a family history of type 2 diabetes" [1].

All tests above can be drawn from a single fasting blood sample collected between 7 and 10 a.m. No special preparation beyond the 8-to-12-hour fast is required. Water intake should continue normally to avoid hemoconcentration.